How to Appeal an Insurance Denial for GLP-1 Medication
The step-by-step process for fighting back — with the documentation strategies that actually win.
Your insurance denied coverage for your GLP-1 medication. It feels like a dead end, but here's what most patients don't know: the denial is often just the first word, not the last. Data suggests that 40–60% of first-level internal appeals succeed when the denial was technical — missing documentation, insufficient clinical history, or incomplete paperwork.
The problem? Fewer than 1% of patients actually appeal. Most accept the denial and either pay out of pocket or give up entirely. This guide walks you through every step of the appeal process so you don't have to be one of them.
Step 1: Read the Denial Letter Carefully
Identify the Denial Reason
Your Explanation of Benefits (EOB) or denial letter must include a specific reason for the denial. This is legally required. The reason determines your entire appeal strategy — you're not writing a generic "please reconsider" letter.
Look for the exact denial code or language. Common categories include "plan exclusion," "not medically necessary," "step therapy required," and "insufficient documentation." Each requires a fundamentally different response.
Step 2: Understand What You're Fighting
| Denial Reason | What It Means | Your Strategy |
|---|---|---|
| Plan Exclusion | Your employer opted out of anti-obesity medication coverage entirely | Don't appeal for weight loss. If you have cardiovascular disease, appeal for Wegovy under its cardiovascular risk reduction indication (ICD-10 I25.10). This changes the clinical basis entirely. |
| Not Medically Necessary | You meet BMI criteria but the insurer says you don't have enough health risk | Submit a Letter of Medical Necessity focusing on metabolic syndrome markers — prediabetes, elevated CRP, fatty liver/MASH, conditions that signal imminent risk even if they haven't yet crossed into full "disease" territory. |
| Step Therapy Required | You haven't tried and failed cheaper medications first (phentermine, Contrave, Qsymia) | Document specific contraindications to each required step. Uncontrolled hypertension contraindicates phentermine. Seizure history contraindicates Contrave (bupropion). Childbearing age raises concerns with Qsymia (teratogenicity). |
| Missing Documentation | Your provider didn't include enough clinical information | The easiest win. Gather the missing documents and resubmit. This is the most common reason for denial — and the most common reason appeals succeed. |
Step 3: File an Internal Appeal
Timeline Matters
You typically have 180 days from the denial date to file an internal appeal for employer-sponsored (ERISA) plans. ACA marketplace plans have similar windows. Don't wait — start gathering documentation immediately.
Build Your Appeal Package
A strong appeal includes several key components. Your Letter of Medical Necessity (LMN) from your prescribing doctor is the centerpiece. This letter should be specific — it needs to map your conditions to ICD-10 codes, cite clinical evidence supporting GLP-1 therapy for your situation, and explain why alternative treatments are inappropriate or have failed.
Clinical documentation to include: BMI history (minimum 3–6 months of recorded weights), lab results showing weight-related conditions (A1c, lipid panel, liver enzymes, fasting glucose), records of prior weight loss attempts with dates and outcomes, sleep study results if applicable, and any specialist notes from endocrinology or obesity medicine.
Evidence that strengthens your case: The SELECT trial showed a 20% reduction in major cardiovascular events with semaglutide. The FDA approved Zepbound specifically for obstructive sleep apnea reduction. These aren't "weight loss" arguments — they're risk reduction arguments, and they change how insurers evaluate medical necessity.
Step 4: Request a Peer-to-Peer Review
The Most Powerful Tool Available
A peer-to-peer (P2P) review is a phone call between your prescribing physician and the insurer's medical director. This is widely considered the most effective strategy for complex denials.
Your doctor's strategy should pivot from "weight loss" to "risk reduction." Framing matters enormously. Instead of arguing that you need medication to lose weight, your doctor argues that denying the medication increases the insurer's risk of paying for a future heart attack, stroke, joint replacement, or CPAP-dependent sleep apnea management.
Step 5: External Review (If Internal Appeal Fails)
If your internal appeal is denied, you have a federal right to an external review by an Independent Review Organization (IRO). This is available under the ACA for marketplace plans and most employer plans. The IRO is an independent third party — not employed by your insurer — that reviews your case against clinical guidelines.
External review decisions are legally binding on the insurer. If the IRO rules in your favor, your insurer must cover the medication. Success rates for external reviews are lower than internal appeals (roughly 27–40%), but IROs tend to follow clinical guidelines from organizations like the ADA and AHA more closely than insurers' internal cost-containment policies.
For Medicare beneficiaries, the appeal pathway is different: Redetermination → Qualified Independent Contractor (QIC) → Administrative Law Judge (ALJ) → Medicare Appeals Council → Federal Court. Each level has specific timelines and documentation requirements.
If the Appeal Fails: Your Options
Not every appeal succeeds. If you've exhausted the appeals process and your insurer still won't cover GLP-1 therapy, you have several paths forward.
Manufacturer savings programs can dramatically reduce out-of-pocket costs. Novo Nordisk offers Wegovy through NovoCare at $199/month for the first two fills and $349/month after that. Eli Lilly offers Zepbound through LillyDirect starting at around $299/month. These aren't available to Medicare or Medicaid beneficiaries, but for commercially insured patients whose coverage was denied, they're often cheaper than using insurance with a high deductible.
HSA and FSA accounts can be used for GLP-1 medications if your doctor provides a Letter of Medical Necessity stating the medication treats a specific diagnosed disease (obesity with ICD-10 code E66.01, type 2 diabetes, hypertension, etc.). General "wellness" use doesn't qualify.
Telehealth providers offering compounded GLP-1 medications provide another route, with all-inclusive monthly pricing that bypasses insurance entirely. If you go this route, verify the provider's credentials and the pharmacy's accreditation carefully.
Need an Affordable Alternative While You Appeal?
Sesame Care offers board-certified clinician consultations at transparent, low prices — no insurance required. Get a clinical evaluation and explore your options.
See Sesame Care Options →Employer-Specific Strategies
If your plan exclusion is employer-driven (which is increasingly common — some major employers have dropped GLP-1 coverage to control costs), you have one additional lever: talking to your HR department. Employers who self-fund their health plans choose what's covered. A well-reasoned request — ideally backed by data showing that GLP-1 coverage reduces downstream healthcare costs — can sometimes result in a policy change, especially if multiple employees are making the same request.
Some employers have introduced conditional coverage through programs like "Total Weight Support" (UnitedHealthcare) or wellness-engagement requirements. Ask specifically whether your employer offers any pathway to coverage that isn't listed in the standard benefit design.
Don't Accept the First No
Insurance denials for GLP-1 medications are common, but they're not always final. The data is clear: patients who appeal have a meaningful chance of success, and patients who don't appeal have a zero percent chance. Start with the denial letter, build your documentation, and work with your doctor to make the strongest possible case.